Shigeru Yasue previously worked with Mitsubishi UFJ Capital, Japanese largest financial group’s venture capital arm for more than twenty years, since 2000. He is a founding member of Mitsubishi UFJ Capital’s Life Science Department. His investment area covers not only Japanese biotechs but also US and European biotechs, together with project finance for the pharmaceutical company’s global clinical studies.　 He served on the board of several portfolio companies and achieved 13 exits including Nasdaq and Tokyo Stock Exchange IPOs, M&A and Success fee payments.